+917069000000 info@cims.org

DR. ANISH CHANDARANA

Dr. Anish Chandarana

Dr. Anish Chandarana

Dr. Anish Chandarana

Interventional Cardiologist

MD, DM (CARDIOLOGY), FACC

Cardiology

anish.chandarana@cims.org

+91 9825096922

CURRICULUM VITAE

DR. ANISH HARJIVANDAS CHANDARANA

PRESENT POSITION AND ADDRESS

Executive Director, Interventional Cardiologist

Care Institute of Medical Sciences (CIMS) Hospital

Nr. Shukan Mall, Off Science City Road, Sola

Ahmedabad- 380060, Gujarat, India

Phone: +91-79-27712771(1-5 lines) , +91-79-30101100

Fax:+91-79- 27712770

DATE OF BIRTH

April 25th, 1971

BIRTHPLACE

Mithapur, Gujarat State, India

CITIZENSHIP

Indian

EDUCATION

08/1988 – 11/1993

M.B.B.S, B.J. Medical Collage, Civil Hospital, Ahmedabad

01/1994 – 01/1997

M.D.(Internal Medicine), B.J. Medical Collage, Civil Hospital, Ahmedabad

01/1997 – 01/1999

D.M.(Cardiology) , B.J. Medical Collage, Institute of Cardiology & Research Centre, Ahmedabad

PROFESSIONAL WORK AND TEACHING POSITIONS

06/1999 – 07/2000

Assistant Professor at Institute of Cardiology and Research Centre, Civil Hospital, Ahmedabad.

10/2000 – 02/2003

Attached to Sterling hospital, As a Consultant and Interventional Cardiologist, Ahmedabad

03/2003 – 10/2009

Attached to SAL Hospital, As a Consultant and Interventional Cardiologist, Teacher for D.N.B. (Cardiology) Program, Ahmedabad

11/2009 – 08/2010

Attached to Sterling hospital, As a Consultant and Interventional Cardiologist, Ahmedabad

08/2010 – Present

Executive Director & Consultant and Interventional Cardiologist, CIMS Hospital, Ahmedabad

HOSPITAL COMMITTEES

08/2010 – Present

Care Institute of Medical Sciences (CIMS), Ahmedabad

Vice Chairman

  • Credentials Committee

Vice Chairman

  • Quality Assurance Committee

Member

  • Patient Satisfaction Committee

Member

  • Facility & Safety & Disaster Management Committee

RESEARCH GRANTS AND CONTRACTS: NIL

MEMBERSHIP / ACTIVITIES IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1998 – Present

  1. Life member of Cardiology Society of India

1999 – Present

  1. Life member of Indian Medical Association

1999 – Present

  1. Life member of Indian College of Interventional Cardiology

2000 – Present

  1. Life member of Indian Academy of Echocardiography

  1. Fellow of American College of Cardiology

JOURNAL EDITORSHIP

  1. Editor in Chief, “Maru Hriday” *

  1. Member, Editorial Board, “Healthy Heart” **

  1. Member, Editorial Board, “CIMS News Care & Cure” *

  1. Member, Editorial Board, “Hriday or Dhadkan” *

  • * These are the Journals Published for Patients and Community People. More than 2,00,000 Copies get circulated in western India.
  • ** This Journal is circulated in 30,000 Physicians / Clinicians in western India.

LICENSURE INFORMATION

1993

MBBB, Medical Council of India

1997

M.D., Medical Council of India

MULTICENTER CLINICAL TRIALS:

Participated as a Co-Principal Investigator OR an Investigator

Indication of Trial

Clinical Phase of Trial (I-IV)

Role in Trial (e.g. Investigator, Co-Investigator)

Status (Ongoing/

Completed)

A Multinational, Randomised, Double-Blind, Placebo controlled Trial to Evaluate the Effect of  Ticagrelor 60 mg twice daily  on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus

Phase III

Principal  Investigator

Ongoing

A prospective study to investigate safety and effectiveness of M’Sure-S (Sirolimus Eluting Coronary Stent)

Registry

Principal  Investigator

Ongoing

Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population with Long Lesion(s) and/or Dual Vessels in Asia .A Prospective, Multi-center, Non-randomized Study

Registry

Principal  Investigator

Ongoing

Safety and Efficacy of Axiostat hemostatic dressing on radial access after percutaneous procedure: A comparative open label study

Investigator initiative study

Principal  Investigator

Ongoing

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study,  Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus

Phase III

Co- Investigator

Ongoing

Pulmonary Atrial Hypertension

Phase III

Co- Investigator

Ongoing

A randomized double-blind placebo-controlled trial for the evaluation of a polycap, low dose aspirin and vitamin D supplementation in primary prevention

Phase III

Co- Investigator

Ongoing

A Multicenter,  Randomized,  Double-Blind, Placebo-Controlled Trial  to  Evaluate  the  Effect  of Dapagliflozin  10  mg  Once  Daily  on the Incidence  of Cardiovascular  Death,  Myocardial Infarction  or Ischemic Stroke in  Patients  with Type  2 Diabetes

Phase III

Co-Investigator

Ongoing

Ticagrelor with Aspirin or alone in high risk patients after coronary intervention

Phase III

Co-Investigator

Ongoing

A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate dual antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting

Phase III

Co- Investigator

Ongoing

Sinus node dysfunction registry phase 1

Registry

Co-Investigator

Ongoing

Sinus node dysfunction registry phase 2

Registry

Co-Investigator

Ongoing

A non-interventional prospective observational Study to Understand the usage pattern of Ticagrelor in Indian patients with acute coronary syndrome

Registry

Co-Investigator

Ongoing

Asian sudden cardiac death in Heart Failure

Registry

Co-Investigator

Ongoing

CRDM implantable cardiac device long term registry

Phase IV

Co-Investigator

Ongoing

IdeNtifying High riSk Patients Post Myocardial Infarction with REduced Left Ventricular Function using External Loop Recorders

Phase IV

Co-Investigator

Ongoing

Improve sudden cardiac arrest study

Phase IV

Co-Investigator

Ongoing

International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure

Phase IV

Co-Investigator

Ongoing

A prospective, single-arm, multi-centre, observational, real world, post-marketing surveillance to evaluate safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions

Phase IV

Co-Investigator

Ongoing

To Evaluate The Role Of Radiation Protection Technology (CardiotrapTM) In Improving Radiation Safety In Diagnostic And Interventional Percutaneous Cardiology Procedures

Investigator initiative study

Co-Investigator

Ongoing

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease.

Phase III

Co- Investigator

Ongoing

Observational study of lipid profiles and treatment at presentation and after 12 weeks of statin therapy among Indian adults presenting with first coronary event

Phase IV

Principal Investigator

Completed

Platelet inhibition in Acute Coronary Syndromes

Phase III

Co-Investigator

Completed

New Guide wire for Crossing Total Occlusions in Coronary Arteries

First–in-man

Co-Investigator

Completed

Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes.

Phase II

Co-Investigator

Completed

Evaluation of the anti-anginal efficacy

Phase III

Co-Investigator

Completed

Long term follow up of antithrombotic management    patterns In Acute Coronary Syndrome patients in Asia

Phase IV

Co-Investigator

Completed

Investigate the association between HR and prognosis of patients with CAD treated with bisoprolol

Phase IV

Principal Investigator

Completed

Newly Diagnosed ACS and T2DM

Phase III

Co-Investigator

Completed

Registry of Atrial Fibrillation: Patient Characteristics and Clinical Management Practices

Phase IV

Co- Investigator

Completed

Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy

PI KP

Phase III

Co-Investigator

Completed

Absorb Extend (2011)

A Continuation in the Clinical Evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) System in the Treatment of Subjects with de novo Native Coronary Artery Lesions

Phase III

Co-Investigator

Completed

CAD-PAD Registry (2013).

Coronary and Peripheral Artery Disease Registry.

Phase IV

Co-Investigator

Completed

Panorama 2  Study (2012)

Medtronic CRDM Implantable Cardiac Device Long Term Registry

Dr. AN

Phase IV

Co-Investigator

Completed

ATLAS Trial

PI KP

Phase III

Co-Investigator

Completed

RUBY registry (For India) (2002)

To evaluate Percusurge / Guardwire Distal Protection Device

(Presented by Dr. Aman, Switzerland )

PI KP

Phase IV

Co-Investigator

Completed

Extract-TIMI 25 Multicenter multinational Trial (2003Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction –Study 25

PI KP

Phase III

Co-Investigator

Completed

OASIS-5 Trial (2004)

To evaluate the  To evaluate the efficacy and safety of fondaparinux  versus Enoxaparin in the acute treatment of  unstable angina or  non ST-segment elevation myocardial infarction acute coronary syndromes

Phase III

Co-Investigator

Completed

OASIS-6 Trial (2004)

To evaluate the efficacy and safety of fondaparinux sodium versus control therapy and Glucose-Insulin-potassium infusion versus control in broad range in Patients with ST  – segment elevation acute myocardial infarction

PI KP

Phase III

Co-Investigator

Completed

TRUST Trial (2004)

To evaluate the safety and efficacy of intravenous Remodulin® in patients( in India) With Pulmonary arterial hypertension (PAH)in 12-week

PI KP

Phase III

Co-Investigator

Completed

Paediatric Hypertension Trial (2005)

Dose ranging study to evaluate the  safety and efficacy of Olmesartan medoxomil in children and adolescents with hypertension

Phase IV

Co-Investigator

Completed

Hypercholesterol study (NK-104-301) (2005)

Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs.Atorvastatin 20 mg (Following Up Titration ) in Patients with Primary Hypercholesterolemia Or Combined Dyslipidemia

Phase III

Co-Investigator

Completed

Neovasc Reducer™ Pilot Study, First in human: (2005)

To evaluate the safety of the Neovasc Reducer™ in the treatment of Ischemic heart Disease (IHD), controlled narrowing of the coronary sinus

Phase III

Co-Investigator

Completed

PAPIRUS Trial: Pilot Study, First in Human: Apollo Hospital (2005)

Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal(REMON Device)

PI KP

Phase III

Co-Investigator

Completed

Export study (2006)

Flow improvement in patients with Acute Myocardial Infarction undergoing either conventional stenting or a strategy of primary aspiration followed by stenting using the Export® Aspiration Catheter: a Prospective, Randomized, Controlled Study

PI KP

Phase III

Co-Investigator

Completed

E-five registry (for India) (2006)

To Evaluate the ‘Real World’ Clinical Performance of the Medtronic Endeavor™ ABT-578 Eluting Coronary Stent System.

Phase III

Co-Investigator

Completed

RELY study (2006)

Randomized Evaluation of Long term anticoagulant therapy comparingEfficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation : prospective, multi-centre, Parallel group, Non-inferiority trial.

PI AN

Phase III

Co-Investigator

Completed

Hypercholesterolemia study (NK-104-307) (2006)

Open label, long-Term (1year) extension study of Pitavastatin 4 mg QD in Patients with Primary Hypercholesterolemia or combined Dyslipidemia

PI KP

Phase III

Co-Investigator

Completed

e-SELECT Registry (2007)

The e-SELECT Registry : A Multicenter Post Marketing Survelliance

Phase IV

Co-Investigator

Completed

Early ACS trial (2007)

Early Glycoprotein Iib/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded  Eptifibatide in the Treatment of Patients with Non- ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)

PI KP

Phase III

Co-Investigator

Completed

PLATO trial (2007).

A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and safety study of AZD6140 Compares with Clopidogrel for prevention of Vascular Events in patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO – A study of PLATelet inhibition and Patient Outcomes.]

PI KP

Phase III

Co-Investigator

Completed

OASIS- 7 trial (2007)

Randomized, multinational, double-blind study, comparing a high loading dose regimen of Clopidogrel versus standard dose in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy

Phase III

Co-Investigator

Completed

New Guidewire OVALUM (2007)

First in Man: A Feasibility study to evaluate safety and efficacy of New Guidewire for Crossing Total Occlusions in Coronary Arteries

Dr. KP

Phase III

Co-Investigator

Completed

Paediatric Hypertension Trial, (2007)

A Randomized, double blind, Placebo-Controlled, Multicenter, Parallel Study Assessing the Efficacy, Safety, and Dose Response of Ramipril for the Treatment of Hypertension in Children and Adolescents

Phase III

Co-Investigator

Completed

Aristotle Trial, (2007)

Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation: Active controlled randomized double blind parallel  arm study to evaluate efficacy and safety of Apixaban in subject with  non valvular Atrial fibrillation

Dr. AN

Phase III

Co-Investigator

Completed

Rocket Trial, (2007)

Multicenter, Randomized, double-blind – dummy, Parallel-group, Non-inferiority Trial Comparing the Efficacy and Safety of Once-daily oral Rivaroxabab (BAY 59-7939) with Adjusted-dose oral Warfarin for the prevention of Stroke and Non-central-nervous-system systemic embolism in Subjects with Non-valvular Atrial Fibrillation

Dr. AN

Phase III

Co-Investigator

Completed

PROTECT Trial (2007)

Patient Related Outcomes with Endeavor versus Cypher stenting Trial: Prospective, multicenter, randomized, two-arm, open-label trial

Dr. KP

Phase III

Co-Investigator

Completed

TMC-CAN-05-02 (2007)

A clinical trial comparing Cangrelor to Clopidogrel in subject who require Percutaneous Coronary Intervention

PI KP

Phase III

Co-Investigator

Completed

TMC-CAN-05-03 (2008)

A clinical Trial comparing treatment with Cangrelor (in combination with usual care) to usual care in subjects who require Percutaneous Coronary Intervention

Pi KP

Phase III

Co-Investigator

Completed

CL  (Ivabradine) (2008)

Evaluation of the anti-anginal efficacy

Dr. KP

Phase III

Co-Investigator

Completed

RE-DEEM (2008)

Randomized Dabigatran Etexilate dose finding study in patients with acute coronary syndromes post index Event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel: Multi-centre, prospective, placebo controlled, group dose escalation trial

Dr. KP

Phase III

Co-Investigator

Completed

Magellan Trial (2008)

A Multicenter, Randomized, parallel-group efficacy superiority study in hospitalize medically ill patients comparing rivaroxaban with Enoxaparin

Dr. AN

Phase III

Co-Investigator

Completed

Borealis Trial, (2008)

A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patient with atrial fibrillation

Dr. An

Phase III

Co-Investigator

Completed

Freedom-PAH

FREEDOM UT –15C Studies (TDE-PH-302 and TDE-PH-304) conducted by United Therapeutics.

PI KP

Phase III

Co-Investigator

Completed

ORBIT – 1

Pilot study to evaluate the safety & performance or the diamond back 360TM orbit Atherectomy system in treating de-NOVO calcified coronary lesions – orbit -1

Phase III

Co-Investigator

Completed

AVERROES

CV 185-048: A Phase 3, Active (Aspirin) Controlled, Randomized, Double-Blind, Parallel arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Dr. AN

Phase III

Co-Investigator

Completed

Red-HF:

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction  and Anemia – 20050222 Amendment 1.

Dr. KP

Phase III

Co-Investigator

Completed

TAK-442-202

A Phase II, double-blind, Randomized, Placebo-controlled study of the safety and Efficacy of TAK-442 in subjects with Acute Coronary Syndrome.

Pi kp

Phase III

Co-Investigator

Completed

EISAI-202

A Randomized, Double-Blind Placebo controlled study of the safety and tolerability of E5555 and its effect on clinical event and biomarkers in patient with Non ST segment Elevation Acute Coronary Syndrome.

PI KP

Phase III

Co-Investigator

Completed

RIVAROXABAN

Randomized, Double Blind, Placebo Controlled, Event Driven, Multi-Center Study To Evaluate The Efficacy And Safety Of Rivaroxaban In Subjects With Recent ACS.

Phase III

Co-Investigator

Completed

Pfizer PAH -B1321001

A Phase 3, Multi Center, Randomized, Double Blind, Placebo Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension.

PI KP

Pfizer

Co i

com

Pfizer PAH – B1321002

A Phase 3, Multi Center, Open Label Study To Evaluate The Long Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension.

PI KP

Phase III

Co-Investigator

Completed

Pfizer PAH -B1321003

A Phase 3, Multi Center, Randomized, Double Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium and Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001.

PI KP

Phase III

Co-Investigator

Completed

LPL STABILITY

A Clinical Outcome Study Of Darapladib Versus Placebo In Subjects With Chronic Coronary Heart Disease To Compare The Incidence Of Major Adverse Cardiovascular Event. (MACE)

PI KP

Phase III

Co-Investigator

Completed

OASIS-8

A Prospective Study Evaluating The Safety Of Two Regimens Of Adjustive Intravenous UFH PCI In High Risk Patients With UA/NSTEMI Initially Treated With Subcutaneous Fondaparinux And Referred For Early Coronary Angiography.

PI KP

Phase III

Co-Investigator

Completed

STEM CELL

A Randomized, Double Blind, Multi Centric, Placebo Controlled, Single Dose, Phase I/II Study Assessing The Safety And Efficacy Of Intravenous Ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cell In Patients With ST Elevated Acute MI  (STEMI) Patient.

PI SG

Phase III

Co-Investigator

Completed

RUBY 1Trial (2010)

A Randomized, Double Blind, Placebo Controlled, Multi Center and Parallel Group Study of the Safety, Tolerability, and Efficacy of YM150 in combination with  Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes.

PI KP

Phase III

Co-Investigator

Completed

AmarinTrial (2010)

A phase 3, multi centre, placebo controlled, randomized, double blind, 12 week study with an open label extension to evaluate the efficacy And

safety of AMR101 in patients with fasting triglyceride levels > 500 mg/dl and < 2000 mg/dl

PI KP.

Phase III

Co-Investigator

Completed

SASHF RTrial (2008)

South Asian Systolic Heart Failure Registry

PI AN

Phase IV

Co-Investigator

Completed

for TRAC HF (2009)

TRAC HF: Ambulatory Monitoring Using External Physiological Sensors in Heart Failure Patients.

PI AN

Phase III

Co-Investigator

Completed

Alecardio trial

Cardiovascular outcomes study  to evaluate the potential of aleglitazar  to reduce reduce  cardiovascular  risk in patients with  recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)

Phase III

Co-Investigator

Completed

Timi 52 trial

A Clinical Outcomes Study of Darapaladib versus Pleacebo in Subjects Following  Acute Coronary Syndrome  to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

PI KP

Phase III

Co-Investigator

Completed

Appraise-2 trial

A Phase 3, Randomized, Double-blind, Evaluation of the safety and Efficacy of Apixaban in subjects with a Recent Acute Coronary Syndrome

PI  KP

Phase III

Co-Investigator

Completed

DOT HF (2009)

DOT-HF- Diagnostic Outcome Trial in Heart Failure

PI  AN

Phase IV

Co-Investigator

Completed

T BEST D Trial (2009)

T-BEST-D: Temporary Bronchial Epicardial Stimulation – Defibrillation Clinical Study Version dated: June 28, 2009

PI  AN

Phase IV

Co-Investigator

Completed

SOLISTICE trial (2011)

A Randomized ,double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infract size, and cardiac function in subjects with myocardial infarction without ST segment elevation

PI KP

Phase III

Co-Investigator

Completed

Study ATTAIN (2011)

a prospective, non-randomized, multi-center, post-market, global clinical  trial to assess left-heart lead implant and complication rate using the  Medtronic Attain Family of left-heart leads and delivery catheters.

PI AN

Phase IV

Co-Investigator

Completed

TIMI (2011)

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase IV Trial to Evaluate the effect of Sexagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke inn patient with Type 2 Diabetes)

PI KP

Phase III

Co-Investigator

Completed

OPTIMIND (2011)

Clinical Outcome of Pacemaker patients

according to pacing Modality and primary Indications

IV

Phase IV

Co-Investigator

Completed

SST (2011)

The Pain free SST (Smart Shock Technology) clinical Study.

PI AN

Phase IV

Co-Investigator

Completed

VISTA 16 study (2011)

Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndrome (ACS). VISTA-16: Vascular Inflammation Suppression to Treat Acute coronary syndrome for 16 weeks

PI KP

Phase III

Co-Investigator

Completed

TAO (2011)

Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy”.

PI KP

Phase III

Co-Investigator

Completed

APOLLO (2011).

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO)

PI KP

Phase III

Co-Investigator

Completed

DELIVER (2011)

DELiverability of Resolute Integrity Stent In all- Comer Vessels and Cross Over Stenting”.

Phase IV

Co-Investigator

Completed

EPICOR ASIA (2011)

Long term follow up of antithrombotic management patterns In Acute Coronary Syndrome patients in Asia.

PI KP

Phase III

Co-Investigator

Completed

REMOTE-EVIA study (2011)

Registry for Pacemaker Offering Therapy Enhancement- EVIA.

PI AN

Phase IV

Co-Investigator

Completed

IHRS study (2011)

Indian Heart Rhythm Society (IHRS) Registry of Atrial Fibrillation: Patient Characteristics and Clinical Management Practices

PI AN

Phase IV

Co-Investigator

Completed

SureScan Study

Pacing System Post-Approval Study, Ahmedabad (2012).

Phase IV

Co-Investigator

Completed

TEACHING AND INVITED LECTURES:

  • Has been a faculty and teacher in all following Conference

JIC – Joint International Conference – 2015,2016,2017,2018 , India

CIMS-CON – 2011, 2012, 2013,2014  Ahmedabad, India

3-C Con – 2006, 2007, 2008, 2009, 2010 Ahmedabad, India

Symposium and Update in Cardiovascular Disease, 2005. Bhopal, India

Comprehensive ECG, Arrhythmia & Electro- Physiology Course, 2006, 2008. Ahmedabad, India

Comprehensive Echocardiography Course, 2002, 2003, 2004. Ahmedabad, India

Updates in Congenital Heart Diseases, 2002, 2003, 2004. Ahmedabad, India

Cardio- Pulmonary Resuscitation and Critical care, 2003, 2006, 2011. Ahmedabad, India

Has delivered more than 1000 lectures in different groups of doctors like different IMA branches, MBBS, MD and Doctors in Gujarat, Rajasthan, M.P and other parts of the country.

Has delivered more than 200 lectures for health awareness to community.

BIBLIOGRAPHY

  1. ARTICLES IN PEER-REVIEWED JOURNALS

  1. “ Anatomical Considerations in Trans-Radial Intervention” – Indian Heart Journal India (First Writer)
  1. Authored a book for educating and creating awareness in common people at large. This is published in 3 languages and donates very important information on heart disease prevention, diagnoses and treatment.

=  “ The Heart : A wonderful gift of god”

=  “ Hriday : Ishwar ni Ek Adbhoot Bakshish”

=  “ Hriday : Ishwar ki Ek Adbhoot Bhent”

It’s great to know your doctor better. That’s why at CIMS Hospital in Gujarat, we try to make patient interaction with the doctor start from your first search online all the way to the hospital. 

We cannot display this gallery

Your doctor believes in patient education. You will find a list of patient education videos here soon to get to know both your doctor and the disease better. CIMS Hospital in Ahmedabad and your doctor believes in transferring as much patient education knowledge as possible and is the process of uploading tons of patient education videos that can help you understand the disease or problems better.

CIMS Hospital was awarded being the best hospital in Gujarat for 2019 by the International Health Care Awards.

CIMS Hospital is a 350-bedded, multi-super speciality and regarded one of the best multi-speciality hospitals of Ahmedabad in Gujarat providing a range of diagnostic and treatment services.

CIMS Hospital has been awarded best hospital for quality in service delivery award at the ABP News presents Healthcare Leadership Awards 2015 held at Mumbai.

CIMS Hospital has been recognized as the Times Health Icon 2018 for being the best Hospital for Oncology and Critical Care. CIMS Hospital also was rated the Best Multispecialty Hospital in Gujarat at the International Healthcare Awards, 2018 held in Delhi.

CIMS Hospital provides world-class treatment and healthcare services in India and the leading heart hospital in Ahmedabad, Gujarat. CIMS Hospital offers the highest quality services and offers treatment to most diseases and medical problems with one of the highest success rates in India.

CIMS Hospital
Care Institute of Medical Sciences
Off Science City Road, Sola, Ahmedabad – 380060
Gujarat, INDIA

24x7 Helpline +91 70 69 00 00 00
Phone: +91 79 2771 2771 or 72
Fax: +91 79 2771 2770
Mobile: +91 98250 66664 or +91 98250 66668
Ambulance: +91 98244 50000
Email: info@cims.org

 

 

 

Forms

Organ Donation Registration Form
Job Application Form